- Home
- AUPH vs ETW Comparison
AUPH vs ETW Comparison
Compare AUPH & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUPH | ETW |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 999.1M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUPH | ETW |
|---|---|---|
| Price | $16.28 | $9.23 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 284.6K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.61% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $265,808,000.00 | N/A |
| Revenue This Year | $21.76 | N/A |
| Revenue Next Year | $16.45 | N/A |
| P/E Ratio | $29.65 | ★ N/A |
| Revenue Growth | ★ 20.62 | N/A |
| 52 Week Low | $6.55 | $6.96 |
| 52 Week High | $16.51 | $8.49 |
Technical Indicators
Market Signals| Indicator | AUPH | ETW |
|---|---|---|
| Relative Strength Index (RSI) | 62.41 | 59.55 |
| Support Level | $15.57 | $9.07 |
| Resistance Level | $16.07 | $9.26 |
| Average True Range (ATR) | 0.47 | 0.06 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 81.46 | 81.58 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.